Data / Form D filings / Cellphire, Inc.
Cellphire, Inc.: Form D filings
Cellphire, Inc., a biotechnology company in Rockville, MD, filed 2 Form D notices with the SEC between 2023 and 2025. The latest, on December 11, 2025, reports $3 million sold of a $3 million offering to 19 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 9430 KEY WEST AVENUE, SUITE 250, Rockville, MD, 20850
- Phone
- (240) 268-2489
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1815181
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | New notice | $3,000,000 | $3,000,000 | 19 | Nov 26, 2025 | sec.gov | |
| Oct 3, 2023 | New notice | $8,000,000 | $2,000,000 | $6,000,000 | 1 | Sep 19, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Pamela Conley | Director | |
| Rafael Jorda | Director | |
| Thomas Dubin | Director | |
| Michael Gaffney | Executive Officer, Director | |
| Derek Woods | Director | |
| Randall Stanicky | Director | |
| James Peake | Director |
Other biotechnology companies in Maryland that filed recently
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
Every Form D from the week of Dec 8, 2025 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Cellphire, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.